Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
August 12 Product: Ascendis Pharmas Yorvipath Indication: Hypoparathyroidism After a long regulatory road, Ascendis Pharma received FDA approval Monday for Yorvipath (TransCon PTH) for the treatment of hypoparathyroidism, a rare endocrine disease characterized by abnormally low levels of the parathyroid hormone
Are you interested in trying GLP-1 Therapy for Binge-Eating Disorder, Emotional Eating, Food Noise, or Overweight
Argument in favor: Others say that if Medicare covers the cost of these drugs, it could help more people afford these medications and improve health and quality of life for people who are overweight
Patients often report a gradual but positive change over weeks of therapy
US$ 27.85
US$ 22.10
US$ 22.17
US$ 20.10
US$ 28.26
